<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762788</url>
  </required_header>
  <id_info>
    <org_study_id>CR-4472</org_study_id>
    <nct_id>NCT00762788</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Several Contact Lenses in Extended Wear</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <brief_summary>
    <textblock>
      The study is to clinically evaluate currently marketed contact lenses when used in an
      extended wear modality of up to seven days/six nights.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Corneal Infiltrative Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Extended wear is defined as 7 days, 6 nights of lens wear, weekly replacement of lenses. Incidence was calculated as the number of subjects with event divided by the total number of subjects assigned to that lens type.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>Occurrence of any Adverse Event by study lens. Incidence was calculated as the number of subjects with event divided by the total number of subjects assigned to that lens type.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>senofilcon A contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACUVUE OASYS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lotrafilcon A contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIGHT&amp;DAY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lotrafilcon B contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>O2Optix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>balafilcon A contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PureVision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comfilcon A contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biofinity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A contact lens</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACUVUE 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>senofilcon A</intervention_name>
    <description>1 week extended wear contact lens</description>
    <arm_group_label>senofilcon A contact lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lotrafilcon A</intervention_name>
    <description>1 week extended wear contact lens</description>
    <arm_group_label>lotrafilcon A contact lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>lotrafilcon B</intervention_name>
    <description>1 week extended wear contact lens</description>
    <arm_group_label>lotrafilcon B contact lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>balafilcon A</intervention_name>
    <description>1 week extended wear contact lens</description>
    <arm_group_label>balafilcon A contact lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>comfilcon A</intervention_name>
    <description>1 week extended wear contact lens</description>
    <arm_group_label>comfilcon A contact lens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>1 week extended wear contact lens</description>
    <arm_group_label>etafilcon A contact lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be of legal age, and be between 18 and 39 years of age.

          -  Signed Written Informed Consent and Investigator to record this on Case Report Form
             (CRF) in appropriate space.

          -  Require a visual correction in both eyes (Monovision not allowed)

          -  Require a soft contact lens spherical correction between -0.50 and -9.00D.

          -  Have an astigmatic correction less than 1.50D in both eyes.

          -  Be able to wear the lens powers available for this study.

          -  Be able to regularly wear the lenses on a 7 day/6 night extended wear basis (e.g. does
             not regularly swim more than once a week)

          -  Be correctable to a visual acuity of 20/30 or better in each eye.

          -  Have normal eyes with no evidence of abnormality or disease. For the purposes of this
             study a normal eye is defined as one having:

          -  No amblyopia.

          -  No evidence of lid abnormality or infection.

          -  No clinically significant slit lamp findings

          -  No other active ocular disease.

          -  No previous ocular surgery.

        Exclusion Criteria:

          -  Requires concurrent ocular medication.

          -  Any systemic illness which would contraindicate lens wear or the medical treatment of
             which would affect vision or successful lens wear.

          -  No Clinically significant (Grade 3 or 4) slit lamp findings including corneal edema,
             corneal vascularization, corneal staining, tarsal abnormalities, bulbar injection, or
             any other abnormality of the cornea that would contraindicate contact lens wear.

          -  Diabetic.

          -  Infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease
             (e.g., HIV).

          -  PMMA or RGP lens wear in the previous 8 weeks.

          -  Has had refractive surgery. Has had eye injury/surgery within 8 weeks immediately
             prior to enrolment for this study.

          -  Abnormal lacrimal secretions.

          -  Pre-existing ocular irritation that would preclude contact lens fitting.

          -  Keratoconus or other corneal irregularity.

          -  Pregnancy, lactating or planning a pregnancy at the time of enrollment only.

          -  Participation in any concurrent clinical trial.

          -  Currently wearing B&amp;L PureVision, Ciba O2 Optix, Ciba Night &amp; Day, CooperVision
             Biofinity, Vistakon ACUVUE® OASYS, or Vistakon ACUVUE®2 on an EW basis

          -  Has had previous adverse event(s) contraindicating EW e.g. MK or greater than 2
             corneal scars which appear to be contact lens related (e.g. not trauma related).

          -  Has had an eye injury or surgery within the last eight weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vision Research Foundation</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>September 11, 2014</results_first_submitted>
  <results_first_submitted_qc>May 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2015</results_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were 350 subjects recruited with 314 subjects being dispensed lenses. These 36 subjects were excluded due to failing to meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Senofilcon A Contact Lens</title>
          <description>ACUVUE OASYS</description>
        </group>
        <group group_id="P2">
          <title>Lotrafilcon A Contact Lens</title>
          <description>NIGHT&amp;DAY</description>
        </group>
        <group group_id="P3">
          <title>Lotrafilcon B Contact Lens</title>
          <description>O2Optix</description>
        </group>
        <group group_id="P4">
          <title>Balafilcon A Contact Lens</title>
          <description>PureVision</description>
        </group>
        <group group_id="P5">
          <title>Comfilcon A Contact Lens</title>
          <description>Biofinity</description>
        </group>
        <group group_id="P6">
          <title>Etafilcon A Contact Lens</title>
          <description>ACUVUE 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Senofilcon A Contact Lens</title>
          <description>ACUVUE OASYS</description>
        </group>
        <group group_id="B2">
          <title>Lotrafilcon A Contact Lens</title>
          <description>NIGHT&amp;DAY</description>
        </group>
        <group group_id="B3">
          <title>Lotrafilcon B Contact Lens</title>
          <description>O2Optix</description>
        </group>
        <group group_id="B4">
          <title>Balafilcon A Contact Lens</title>
          <description>PureVision</description>
        </group>
        <group group_id="B5">
          <title>Comfilcon A Contact Lens</title>
          <description>Biofinity</description>
        </group>
        <group group_id="B6">
          <title>Etafilcon A Contact Lens</title>
          <description>ACUVUE 2</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="43"/>
            <count group_id="B6" value="52"/>
            <count group_id="B7" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Data was collected on those subjects 18 years and older, there were no pediatric patients enrolled in the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="3.2"/>
                    <measurement group_id="B2" value="21.6" spread="4.9"/>
                    <measurement group_id="B3" value="19.8" spread="1.7"/>
                    <measurement group_id="B4" value="21.0" spread="3.7"/>
                    <measurement group_id="B5" value="19.5" spread="1.3"/>
                    <measurement group_id="B6" value="20.6" spread="3.6"/>
                    <measurement group_id="B7" value="20.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Corneal Infiltrative Events</title>
        <description>Extended wear is defined as 7 days, 6 nights of lens wear, weekly replacement of lenses. Incidence was calculated as the number of subjects with event divided by the total number of subjects assigned to that lens type.</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects who were enrolled and dispensed lenses.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Contact Lens</title>
            <description>ACUVUE OASYS</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon A Contact Lens</title>
            <description>NIGHT&amp;DAY</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B Contact Lens</title>
            <description>O2Optix</description>
          </group>
          <group group_id="O4">
            <title>Balafilcon A Contact Lens</title>
            <description>PureVision</description>
          </group>
          <group group_id="O5">
            <title>Comfilcon A Contact Lens</title>
            <description>Biofinity</description>
          </group>
          <group group_id="O6">
            <title>Etafilcon A Contact Lens</title>
            <description>ACUVUE 2</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Corneal Infiltrative Events</title>
          <description>Extended wear is defined as 7 days, 6 nights of lens wear, weekly replacement of lenses. Incidence was calculated as the number of subjects with event divided by the total number of subjects assigned to that lens type.</description>
          <population>Subjects who were enrolled and dispensed lenses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="O2" value="16" lower_limit="8" upper_limit="27"/>
                    <measurement group_id="O3" value="10" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O4" value="8" lower_limit="3" upper_limit="17"/>
                    <measurement group_id="O5" value="33" lower_limit="20" upper_limit="47"/>
                    <measurement group_id="O6" value="10" lower_limit="4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events</title>
        <description>Occurrence of any Adverse Event by study lens. Incidence was calculated as the number of subjects with event divided by the total number of subjects assigned to that lens type.</description>
        <time_frame>52 weeks</time_frame>
        <population>Subjects who were enrolled and dispensed lenses.</population>
        <group_list>
          <group group_id="O1">
            <title>Senofilcon A Contact Lens</title>
            <description>ACUVUE OASYS</description>
          </group>
          <group group_id="O2">
            <title>Lotrafilcon A Contact Lens</title>
            <description>NIGHT&amp;DAY</description>
          </group>
          <group group_id="O3">
            <title>Lotrafilcon B Contact Lens</title>
            <description>O2Optix</description>
          </group>
          <group group_id="O4">
            <title>Balafilcon A Contact Lens</title>
            <description>PureVision</description>
          </group>
          <group group_id="O5">
            <title>Comfilcon A Contact Lens</title>
            <description>Biofinity</description>
          </group>
          <group group_id="O6">
            <title>Etafilcon A Contact Lens</title>
            <description>ACUVUE 2</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Occurrence of any Adverse Event by study lens. Incidence was calculated as the number of subjects with event divided by the total number of subjects assigned to that lens type.</description>
          <population>Subjects who were enrolled and dispensed lenses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="23" upper_limit="48"/>
                    <measurement group_id="O2" value="24" lower_limit="15" upper_limit="37"/>
                    <measurement group_id="O3" value="19" lower_limit="10" upper_limit="33"/>
                    <measurement group_id="O4" value="31" lower_limit="21" upper_limit="43"/>
                    <measurement group_id="O5" value="37" lower_limit="24" upper_limit="52"/>
                    <measurement group_id="O6" value="12" lower_limit="5" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Significant Events were defined as events that are usually symptomatic and warrant either temporary or permanent discontinuation of lens wear. Non-significant Events were defined as events that are usually asymptomatic and do not warrant discontinuation of lens wear.</desc>
      <group_list>
        <group group_id="E1">
          <title>Senofilcon A Contact Lens</title>
          <description>ACUVUE OASYS</description>
        </group>
        <group group_id="E2">
          <title>Lotrafilcon A Contact Lens</title>
          <description>NIGHT&amp;DAY</description>
        </group>
        <group group_id="E3">
          <title>Lotrafilcon B Contact Lens</title>
          <description>O2Optix</description>
        </group>
        <group group_id="E4">
          <title>Balafilcon A Contact Lens</title>
          <description>PureVision</description>
        </group>
        <group group_id="E5">
          <title>Comfilcon A Contact Lens</title>
          <description>Biofinity</description>
        </group>
        <group group_id="E6">
          <title>Etafilcon A Contact Lens</title>
          <description>ACUVUE 2</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Microbial Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CLPU</sub_title>
                <description>CLPU = Contact Lens Peripheral Ulcer; significant adverse event</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>SIE</sub_title>
                <description>SIE = Significant Infiltrative Event; significant adverse event</description>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>New Corneal Scar</sub_title>
                <description>New corneal scar without positive history; significant adverse events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Other Significant</sub_title>
                <description>Not specifically identified due to low counts of individual events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>SLF Grade 2 or Less requiring Treatment</sub_title>
                <description>Slit lamp finding of Grade 1 or 2 (on 0-4 scale)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Other Non-significant</sub_title>
                <description>Not specifically identified due to low counts of individual events</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Cautions for results: low completed enrollment numbers and number of non-neophytes lower than required per protocol. Arms not gender matched; Proportion of neophytes/non-neophytes not balanced; High rate of drop-out among subjects enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathy Osborn, OD, MS, FAAO, FBCLA Senior Principal Research Optometrist</name_or_title>
      <organization>Vistakon</organization>
      <phone>1 904 443-1032</phone>
      <email>kosborn@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

